Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop (iDCL) Trial.

Laya EkhlaspourDan RaghinaruGregory P ForlenzaElvira IsganaitisYogish C KudvaDavid W LamCamilla LevisterGrenye O'MalleyMei Mei Church John W Lum Bruce A BuckinghamSue A Brown

Published in: Journal of diabetes science and technology (2022)

There was a consistent benefit in patients with T1D when using CLC, regardless of baseline insulin delivery modality or CGM use. These data suggest that this CLC system can be considered across a wide range of patients.

Keyphrases

type diabetes
end stage renal disease
glycemic control
ejection fraction
newly diagnosed
chronic kidney disease
clinical trial
study protocol
peritoneal dialysis
prognostic factors
randomized controlled trial
electronic health record
big data
adipose tissue
skeletal muscle
deep learning